ALK-Abelló Toekomstige groei
Future criteriumcontroles 3/6
ALK-Abelló zal naar verwachting groeien in winst en omzet met respectievelijk 15% en 12.3% per jaar. De winst per aandeel zal naar verwachting groeien met 15% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 19.8% zijn.
Belangrijke informatie
15.0%
Groei van de winst
15.03%
Groei van de winst per aandeel
| Pharmaceuticals winstgroei | 10.7% |
| Inkomstengroei | 12.3% |
| Toekomstig rendement op eigen vermogen | 19.80% |
| Dekking van analisten | Low |
| Laatst bijgewerkt | 05 May 2026 |
Recente toekomstige groei-updates
Recent updates
Narratiefupdate • Apr 24
ALK B: Future Upside Will Come From Needle Free Anaphylaxis Treatment Adoption
Analysts have nudged their price target for ALK-Abelló to DKK 263.33 from DKK 255, reflecting updated assumptions around slightly adjusted revenue growth, profit margin expectations, and a higher future P/E multiple. What's in the News ALK reported positive topline phase 2 data from the ALLIANCE trial of its once daily sublingual immunotherapy tablet for peanut allergy in patients aged 4 to 65 years, with statistically significant, dose dependent efficacy across multiple tolerated dose and eliciting dose endpoints and a safety profile without treatment related anaphylaxis or serious adverse events (Key Developments).Narratiefupdate • Apr 09
ALK B: Future Upside Will Come From Wider Needle Free Anaphylaxis Treatment Adoption
Analysts have adjusted their DKK price targets for ALK-Abelló to reflect updated assumptions for revenue growth of 13.31%, profit margin of 20.66% and a future P/E of 34.79. This suggests a modest recalibration in how the company’s earnings power is being valued.Narratiefupdate • Mar 25
ALK B: Future Upside Will Rely On Wider Anaphylaxis Spray Adoption
Analysts have kept their DKK price target for ALK-Abelló broadly unchanged at DKK 255, reflecting stable assumptions on fair value, discount rate, revenue growth, profit margin and future P/E. This signals a steady view on the company’s outlook.Narratiefupdate • Mar 11
ALK B: Future Upside Will Rely On Wider Anaphylaxis Treatment Adoption
Analysts have kept their DKK 255.00 price target for ALK-Abelló unchanged, indicating that their views on fair value, discount rate, expected revenue growth, profit margin and future P/E assumptions remain broadly steady. What's in the News ALK-Abelló presented late-breaking data from a 90-participant study comparing needle-free EURneffy nasal adrenaline to injectable auto-injectors for anaphylaxis, with 88% of participants preferring EURneffy, mainly for ease of use, portability and the absence of a needle (AAAAI 2026 Annual Meeting).Narratiefupdate • Feb 25
ALK B: Future Returns Will Rely On Expanded Anaphylaxis Indications And Stronger Margins
Analysts have nudged their price target on ALK-Abelló up from DKK 249 to DKK 255, reflecting updated assumptions that combine slightly lower expected revenue growth with a higher projected profit margin and a modestly lower future P/E multiple. What's in the News ALK Abelló issued earnings guidance for 2026, indicating an expectation of continued double digit revenue growth and higher earnings, with revenue projected to grow 11 to 15% in local currencies (company guidance).Narratiefupdate • Feb 10
ALK B: Future Returns Will Rely On Expanded Anaphylaxis Reach And Higher 2025 Margins
Analysts have lifted their fair value estimate for ALK-Abelló from DKK 214 to DKK 249, citing updated assumptions around discount rates, revenue growth, profit margins and future P/E levels. What's in the News The Committee for Medicinal Products for Human Use of the European Medicines Agency issued a positive opinion recommending EU marketing authorisation for EURneffy 1 mg nasal adrenaline spray for emergency treatment of anaphylaxis in children aged 4 years and older weighing 15 kg to 30 kg.Narratiefupdate • Jan 27
ALK B: Future Returns Will Reflect Upgraded 2025 Outlook And Stable Margin Ambitions
Analysts have kept their price target for ALK-Abelló steady at DKK 214. This reflects unchanged assumptions around discount rate, revenue growth, profit margin and future P/E, and indicates that new research has not materially shifted their valuation view.
Nieuw narratief • Jan 23
Pediatric Allergy Tablets And Food Programs Will Drive A Long Runway Of Opportunity
Catalysts About ALK-Abelló ALK Abelló develops and commercialises allergy immunotherapy tablets, injectable and drop therapies, along with anaphylaxis treatments such as Jext and neffy. What are the underlying business or industry changes driving this perspective?Analyseartikel • Jan 23
ALK-Abelló (CPH:ALK B) Seems To Use Debt Quite Sensibly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Narratiefupdate • Jan 12
ALK B: Future Returns Will Reflect Upgraded Outlook And Balanced Margin Prospects
Analysts have trimmed their price target for ALK-Abelló to €214.00 from €219.33, citing updated assumptions that now reflect slightly higher revenue growth, a modestly lower profit margin outlook and a small adjustment to the projected future P/E multiple. What's in the News ALK-Abelló upgraded its earnings guidance for the full year 2025, with expected revenue growth of 13% to 15% in local currencies, compared with a previous range of 12% to 14% (Key Developments).Narratiefupdate • Dec 19
ALK B: Future Returns Will Reflect Upgraded Outlook And Solid Margin Prospects
Analysts have modestly lifted their average price target on ALK-Abelló to DKK 219.33, reflecting steady confidence in the company’s unchanged long term growth, margin, and valuation assumptions despite minimal adjustments to underlying model inputs. What's in the News Upgraded 2025 revenue guidance to 13% to 15% growth in local currencies, from 12% to 14%, supported by stronger demand across all regions and product lines (company guidance).Analyseartikel • Dec 08
Investors Appear Satisfied With ALK-Abelló A/S' (CPH:ALK B) Prospects
With a price-to-earnings (or "P/E") ratio of 45.8x ALK-Abelló A/S ( CPH:ALK B ) may be sending very bearish signals at...Narratiefupdate • Dec 05
ALK B: Future Returns Will Reflect China Alliance And Margin Outlook
Analysts have maintained their DKK 219.33 price target for ALK Abelló, reflecting stable expectations for sustained double digit revenue growth, robust profit margins and a premium future P E multiple. What's in the News Upgraded 2025 guidance, with expected revenue growth raised to 13% to 15% in local currencies, supported by higher treatment volumes across allergy immunotherapy and anaphylaxis products, and an improved projected EBIT margin of about 26% (company guidance).Narratiefupdate • Nov 21
ALK B: Improved Margins and China Partnership Will Drive Steady Outlook
Analysts have raised their price target for ALK-Abelló to DKK 219.33 from DKK 196.00. They cite ongoing improvements in profit margins and a slightly higher projected fair value as the reasons for the adjustment.Analyseartikel • Nov 15
ALK-Abelló A/S (CPH:ALK B) Just Reported And Analysts Have Been Lifting Their Price Targets
It's been a pretty great week for ALK-Abelló A/S ( CPH:ALK B ) shareholders, with its shares surging 15% to kr.230 in...Narratiefupdate • Nov 04
ALK B: Chinese Partnership And Revenue Upside Will Drive Future Opportunities
Analysts have raised their price target for ALK-Abelló from DKK 193 to DKK 196. This change is based on slightly improved revenue growth estimates and valuation adjustments.Analyseartikel • Oct 11
Does ALK-Abelló (CPH:ALK B) Have A Healthy Balance Sheet?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Narratiefupdate • Aug 23
Allergy+ Strategy Will Reach Millions With New Therapies
The increase in ALK-Abelló’s analyst price target is primarily driven by a modest upward revision in consensus revenue growth forecasts, while net profit margins remain steady, resulting in a new fair value estimate of DKK192.33 per share. What's in the News ALK-Abelló raised its 2025 revenue growth guidance to 12-14% (from 9-13%) in local currencies, supported by strong adrenaline autoinjector and tablet sales in Europe and North America, and will allocate additional funds to strategic growth investments.Analyseartikel • Jul 23
ALK-Abelló A/S' (CPH:ALK B) Popularity With Investors Is Clear
With a price-to-earnings (or "P/E") ratio of 44.9x ALK-Abelló A/S ( CPH:ALK B ) may be sending very bearish signals at...Analyseartikel • Jun 17
ALK-Abelló (CPH:ALK B) Seems To Use Debt Quite Sensibly
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Nieuw narratief • Dec 11
Allergy+ Strategy And Neffy Nasal Spray Will Ignite Revenue Growth And Boost Earnings
The Allergy+ strategy and neffy nasal spray deal are expected to create new revenue streams and drive growth from 2025 onward.Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2028 | 9,330 | 1,862 | 1,427 | 1,861 | 4 |
| 12/31/2027 | 8,257 | 1,639 | 1,223 | 1,667 | 4 |
| 12/31/2026 | 7,277 | 1,444 | 1,051 | 1,512 | 4 |
| 3/31/2026 | 6,561 | 1,280 | 1,796 | 2,189 | N/A |
| 12/31/2025 | 6,312 | 1,197 | 1,457 | 1,817 | N/A |
| 9/30/2025 | 6,078 | 1,101 | 218 | 1,548 | N/A |
| 6/30/2025 | 5,861 | 999 | 70 | 1,380 | N/A |
| 3/31/2025 | 5,708 | 937 | 18 | 1,319 | N/A |
| 12/31/2024 | 5,537 | 815 | -90 | 1,213 | N/A |
| 9/30/2024 | 5,383 | 785 | 777 | 1,086 | N/A |
| 6/30/2024 | 5,180 | 690 | 724 | 1,046 | N/A |
| 3/31/2024 | 4,941 | 555 | 449 | 796 | N/A |
| 12/31/2023 | 4,824 | 486 | 288 | 667 | N/A |
| 9/30/2023 | 4,728 | 424 | 17 | 426 | N/A |
| 6/30/2023 | 4,680 | 359 | -76 | 343 | N/A |
| 3/31/2023 | 4,590 | 335 | 90 | 479 | N/A |
| 12/31/2022 | 4,511 | 335 | 63 | 416 | N/A |
| 9/30/2022 | 4,361 | 333 | 149 | 489 | N/A |
| 6/30/2022 | 4,227 | 318 | 163 | 493 | N/A |
| 3/31/2022 | 4,050 | 255 | 152 | 432 | N/A |
| 12/31/2021 | 3,916 | 219 | 205 | 468 | N/A |
| 9/30/2021 | 3,808 | 112 | 273 | 505 | N/A |
| 6/30/2021 | 3,652 | 55 | 158 | 358 | N/A |
| 3/31/2021 | 3,556 | 66 | 147 | 358 | N/A |
| 12/31/2020 | 3,491 | 25 | 79 | 301 | N/A |
| 9/30/2020 | 3,383 | 43 | 87 | 298 | N/A |
| 6/30/2020 | 3,350 | 49 | 149 | 353 | N/A |
| 3/31/2020 | 3,363 | -9 | -14 | 172 | N/A |
| 12/31/2019 | 3,274 | -50 | N/A | 132 | N/A |
| 9/30/2019 | 3,178 | -183 | N/A | 59 | N/A |
| 6/30/2019 | 3,100 | -200 | N/A | -54 | N/A |
| 3/31/2019 | 3,030 | -149 | N/A | -27 | N/A |
| 12/31/2018 | 2,915 | -170 | N/A | -95 | N/A |
| 9/30/2018 | 2,891 | -183 | N/A | -223 | N/A |
| 6/30/2018 | 2,897 | -152 | N/A | -214 | N/A |
| 3/31/2018 | 2,873 | -136 | N/A | -386 | N/A |
| 12/31/2017 | 2,910 | -158 | N/A | -387 | N/A |
| 9/30/2017 | 2,901 | 37 | N/A | -278 | N/A |
| 6/30/2017 | 2,864 | 76 | N/A | -146 | N/A |
| 3/31/2017 | 2,946 | 149 | N/A | 206 | N/A |
| 12/31/2016 | 3,005 | 270 | N/A | 405 | N/A |
| 9/30/2016 | 2,938 | 373 | N/A | 492 | N/A |
| 6/30/2016 | 2,975 | 396 | N/A | 458 | N/A |
| 3/31/2016 | 2,767 | 378 | N/A | 312 | N/A |
| 12/31/2015 | 2,569 | 344 | N/A | 183 | N/A |
| 9/30/2015 | 2,494 | 221 | N/A | 153 | N/A |
| 6/30/2015 | 2,349 | 185 | N/A | 136 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachte winstgroei ALK B ( 15% per jaar) ligt boven de spaarquote ( 2% ).
Winst versus markt: De winst van ALK B ( 15% per jaar) zal naar verwachting sneller groeien dan de Danish markt ( 9.2% per jaar).
Hoge groeiwinsten: De winst van ALK B zal naar verwachting groeien, maar niet aanzienlijk.
Omzet versus markt: De omzet van ALK B ( 12.3% per jaar) zal naar verwachting sneller groeien dan de markt Danish ( 3.8% per jaar).
Hoge groei-inkomsten: De omzet van ALK B ( 12.3% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Het rendement op eigen vermogen ALK B zal naar verwachting over 3 jaar laag zijn ( 19.8 %).
Ontdek groeibedrijven
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/05/24 18:24 |
| Aandelenkoers aan het einde van de dag | 2026/05/22 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
ALK-Abelló A/S wordt gevolgd door 8 analisten. 4 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| null null | ABG Sundal Collier |
| Jesper Ilsoe | Carnegie Investment Bank AB |
| Jesper Ingildsen | DNB Carnegie |